GLP-1 Receptor Agonists · Comparison

GLP-1 Agonist Comparison Matrix

For Research Use Only. Not for Human or Veterinary Use.

Overview

A side-by-side comparison of the three incretin-based agonists in this database — Tirzepatide (dual GIP/GLP-1), Retatrutide (triple GIP/GLP-1/glucagon) and Semaglutide (selective GLP-1) — across chemistry, receptor pharmacology, pharmacokinetics, safety and research positioning.

Overview

FeatureTirzepatideRetatrutideSemaglutide
ClassGIP/GLP-1 dualGIP/GLP-1/GCGR tripleSelective GLP-1
OriginatorEli LillyEli LillyNovo Nordisk
Development statusMarketed / studiedInvestigational (Phase 3)Marketed / studied
Study routeSC weeklySC weeklySC weekly / oral daily
Half-life≈ 5 days≈ 6 days≈ 7 days

Chemical Comparison

PropertyTirzepatideRetatrutideSemaglutide
CAS number2023788-19-22381089-83-3910463-68-2
Molecular formulaC₂₂₅H₃₄₈N₄₈O₆₈≈ C₂₂₈H₃₅₄N₄₆O₆₈C₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight4813.45≈ 4840.584113.58
Sequence length39 aa39 aa31 aa
Fatty-acid modificationC20 diacidC20 diacidC18 diacid
Purity (HPLC)≥ 98%≥ 98%≥ 98%

Receptor Pharmacology Comparison

ReceptorTirzepatideRetatrutideSemaglutide
GLP-1RActiveActiveActive
GIPRActiveActiveInactive
Glucagon receptor (GCGR)InactiveActiveInactive
ProfileBalanced GIP/GLP-1Balanced tripleSelective GLP-1

Pharmacokinetic Comparison

ParameterTirzepatideRetatrutideSemaglutide
Bioavailability (SC)≈ 80%≈ 75%≈ 89%
Tmax8–24 h12–24 h12–24 h
Volume of distribution≈ 0.3 L/kg≈ 0.25 L/kg≈ 0.3 L/kg
Protein binding≈ 99%≈ 99%≈ 99%
MetabolismProteolyticProteolyticProteolytic
EliminationRenal / fecalRenal / fecalRenal / fecal

Research Evidence Comparison

A qualitative view of research focus and positioning (research context; specific numerical outcomes are not restated as claims):

Research areaTirzepatideRetatrutideSemaglutide
Type-2-diabetes researchExtensiveEmerging (Phase 2/3)Extensive
Obesity / body-weight researchExtensiveActive (Phase 2/3)Extensive
Cardiovascular-outcome researchOngoingEarlyExtensive
Glucagon-receptor (energy expenditure)NoYes (defining feature)No
Oral-route researchNoNoYes

Safety Profile Comparison

Published safety observations, provided as research reference only; none of these compounds is for human or veterinary use.

ObservationTirzepatideRetatrutideSemaglutide
GI tolerabilityDose-dependent GI eventsDose-dependent GI eventsDose-dependent GI events
Pancreatitis / gallbladderLow frequencyLow frequencyLow frequency
Heart-rate increaseReportedReportedReported
Thyroid C-cell (rodent)Yes (class effect)Yes (class effect)Yes (class effect)

Dosing Comparison (Research)

Reconstitution-oriented reference ranges from the literature; not human dosing guidance.

ParameterTirzepatideRetatrutideSemaglutide
Research range (weekly, SC)0.25–2.0 mg0.25–1.2 mg0.25–2.4 mg
Escalation interval≈ 4 weeks≈ 4 weeks≈ 4 weeks
RouteSCSCSC / oral

Selection Considerations

Choose Tirzepatide when

The research needs both GIP and GLP-1 activation, or a head-to-head against selective GLP-1 agonism.

Choose Retatrutide when

Triple activation is the point — especially the glucagon-receptor contribution to energy expenditure.

Choose Semaglutide when

A well-characterized selective GLP-1 agonist is needed, or the study focuses on cardiovascular outcomes or the oral route.

Analytical Method Comparison

ParameterTirzepatideRetatrutideSemaglutide
HPLC gradient20–60% B25–65% B20–60% B
ColumnC18 (4.6 × 250 mm)C18 (4.6 × 250 mm)C18 (4.6 × 250 mm)
DetectionUV 214 nmUV 214 nmUV 214 nm
MS ionizationESI+ESI+ESI+
Charge states≈ +4 to +8≈ +4 to +8≈ +3 to +7

Selected References

  • Coskun T, et al. Dual GIP/GLP-1 agonist tirzepatide. Diabetes, 2018.
  • Coskun T, et al. Triple GIP/GLP-1/glucagon agonist retatrutide. Nature Metabolism, 2022.
  • Frías JP, et al. Tirzepatide versus semaglutide (SURPASS-2). The Lancet, 2021.
  • Marso SP, et al. Semaglutide and cardiovascular outcomes (SUSTAIN-6). New England Journal of Medicine, 2016.
  • Wilding JPH, et al. Once-weekly semaglutide for obesity (STEP-1). New England Journal of Medicine, 2021.

Quality & Supply

  • All three agonists available research-grade, HPLC-characterized with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS; endotoxin tested by LAL
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need GLP-1 Agonist Comparison Matrix — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote